Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Soy peptide + chemo drug block colon cancer's spread to liver

20.09.2011
A University of Illinois study reports a promising new weapon in treating metastatic colon cancer, particularly in patients who have developed resistance to chemotherapy.

U of I researcher Elvira de Mejia has found that the soy peptide lunasin binds to a specific receptor in highly metastatic colon cancer cells, preventing them from attaching to the liver.

"When lunasin was used in combination with the chemotherapy drug oxaliplatin, we saw a sixfold reduction in the number of new tumor sites," said de Mejia, a U of I associate professor of food chemistry and food toxicology.

The study appears in the most recent issue of Cancer Letters and can be accessed online at http://www.sciencedirect.com/science/article/pii/S0304383511005325 . In a separate study, the scientists showed that lunasin induces cell death in highly metastatic human colon cancer cells.

According to de Mejia, almost all colon cancer deaths are caused when cancer metastasizes—or spreads—to the liver. Until now chemotherapy has targeted the primary tumor because the process of metastasis is not well understood, she said.

"In this study, we have learned that lunasin can penetrate the cancer cell, cause cell death, and interact with at least one type of receptor in a cell that is ready to metastasize," said Vermont P. Dia, a U of I postdoctoral fellow in the de Mejia laboratory and lead author of the study.

When that receptor is blocked, new blood vessels can't form and differentiate, and that prevents cancer from spreading. Binding such receptors has emerged as a promising target for developing cancer therapies, he said.

In the study, which mimicked the spread of colon cancer in humans, mice were separated into four groups: a control group; a group that was injected daily with lunasin; a group injected with the chemo drug oxaliplatin; and a group that received both lunasin and oxaliplatin. After 28 days, the mice were examined to learn the extent of cancer's involvement in the liver.

"The group that received lunasin alone had 50 percent fewer metastatic sites. But an even more exciting result was seen in the group that received both lunasin and the chemotherapy drug—only 5 new cancer sites when compared with 28 in the control group," de Mejia noted.

"This huge reduction in metastasis was achieved with the amount of lunasin in only 25 daily grams of soy protein, the amount recommended in the FDA health claim," Dia said.

The researchers said they recently analyzed commercial soy milks available in their area, and all contained lunasin. However, the amount of lunasin depended on the type of soy product that was used to prepare the soy milk.

"Two glasses of soy milk a day generally provide half the amount of lunasin used in our study," said de Mejia. "It certainly seems feasible to create a lunasin-enriched product that people could consume in a preventive way."

The scientists said their next step will be a colon cancer study in which they make lunasin part of the animals' diet—rather than injecting the peptide—to see if digestion and absorption alter its effectiveness. Soon they hope to be able to move on to human trials.

Dia received the American Oil Chemists Society's 2011 Hans Kaunitz Award for his work with lunasin.

Vermont P. Dia and Elvira de Mejia of the U of I are co-authors of both the study published in Cancer Letters and the in vitro study of lunasin's effect on human cancer cells published in Molecular Nutrition & Food Research, vol. 55, p. 623-634, 2011, available online at www://onlinelibrary.wiley.com/doi/10.1002/mnfr.201000419/pdf. Funding was provided by the USDA, the U of I College of ACES Office of Research, and the Illinois Soybean Association.

Phyllis Picklesimer | EurekAlert!
Further information:
http://www.illinois.edu

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Underwater acoustic localization of marine mammals and vehicles

23.11.2017 | Information Technology

Enhancing the quantum sensing capabilities of diamond

23.11.2017 | Physics and Astronomy

Meadows beat out shrubs when it comes to storing carbon

23.11.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>